These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 9788011

  • 1. MDMA ('ecstasy') consumption in the context of polydrug abuse: a report on 150 patients.
    Schifano F, Di Furia L, Forza G, Minicuci N, Bricolo R.
    Drug Alcohol Depend; 1998 Sep 01; 52(1):85-90. PubMed ID: 9788011
    [Abstract] [Full Text] [Related]

  • 2. Potential human neurotoxicity of MDMA ('Ecstasy'): subjective self-reports, evidence from an Italian drug addiction centre and clinical case studies.
    Schifano F.
    Neuropsychobiology; 2000 Sep 01; 42(1):25-33. PubMed ID: 10867553
    [Abstract] [Full Text] [Related]

  • 3. [A case of acute psychotic episode after a single dose of ecstasy].
    Vaiva G, Bailly D, Boss V, Thomas P, Lestavel P, Goudemand M.
    Encephale; 2001 Sep 01; 27(2):198-202. PubMed ID: 11407274
    [Abstract] [Full Text] [Related]

  • 4. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage?
    Gouzoulis-Mayfrank E, Daumann J.
    Addiction; 2006 Mar 01; 101(3):348-61. PubMed ID: 16499508
    [Abstract] [Full Text] [Related]

  • 5. Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy').
    McCann UD, Slate SO, Ricaurte GA.
    Drug Saf; 1996 Aug 01; 15(2):107-15. PubMed ID: 8884162
    [Abstract] [Full Text] [Related]

  • 6. Recreational ecstasy/MDMA and other drug users from the UK and Italy: psychiatric symptoms and psychobiological problems.
    Parrott AC, Milani RM, Parmar R, Turner JD.
    Psychopharmacology (Berl); 2001 Dec 01; 159(1):77-82. PubMed ID: 11797073
    [Abstract] [Full Text] [Related]

  • 7. Self-reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal investigation.
    Daumann J, Hensen G, Thimm B, Rezk M, Till B, Gouzoulis-Mayfrank E.
    Psychopharmacology (Berl); 2004 May 01; 173(3-4):398-404. PubMed ID: 14722704
    [Abstract] [Full Text] [Related]

  • 8. [Psychiatric disorders and consumption of ecstasy drug (MDMA): review of published case reports].
    Bango J, Fadón P, Mata F, Rubio G, Santo-Domingo J.
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1998 May 01; 26(4):260-3. PubMed ID: 9807860
    [Abstract] [Full Text] [Related]

  • 9. Memory deficits associated with recreational use of "ecstasy" (MDMA).
    Morgan MJ.
    Psychopharmacology (Berl); 1999 Jan 01; 141(1):30-6. PubMed ID: 9952062
    [Abstract] [Full Text] [Related]

  • 10. The dark side of ecstasy: neuropsychiatric symptoms after exposure to 3,4-methylenedioxymethamphetamine.
    Karlsen SN, Spigset O, Slørdal L.
    Basic Clin Pharmacol Toxicol; 2008 Jan 01; 102(1):15-24. PubMed ID: 18047478
    [Abstract] [Full Text] [Related]

  • 11. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
    Thomasius R, Zapletalova P, Petersen K, Buchert R, Andresen B, Wartberg L, Nebeling B, Schmoldt A.
    J Psychopharmacol; 2006 Mar 01; 20(2):211-25. PubMed ID: 16510479
    [Abstract] [Full Text] [Related]

  • 12. Attributions for psychobiological changes in ecstasy/MDMA and other polydrug users.
    Soar K, Parrott A, Turner J.
    J Psychopharmacol; 2009 Sep 01; 23(7):745-58. PubMed ID: 18635698
    [Abstract] [Full Text] [Related]

  • 13. Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study.
    de Sola Llopis S, Miguelez-Pan M, Peña-Casanova J, Poudevida S, Farré M, Pacifici R, Böhm P, Abanades S, Verdejo García A, Langohr K, Zuccaro P, de la Torre R.
    J Psychopharmacol; 2008 Jul 01; 22(5):498-510. PubMed ID: 18208910
    [Abstract] [Full Text] [Related]

  • 14. Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users.
    Parrott AC, Sisk E, Turner JJ.
    Drug Alcohol Depend; 2000 Jul 01; 60(1):105-10. PubMed ID: 10821995
    [Abstract] [Full Text] [Related]

  • 15. [Psychological aspects of MDMA (ecstasy) users].
    Varescon I.
    Ann Med Interne (Paris); 2003 Nov 01; 154 Spec No 2():S81-5. PubMed ID: 14760230
    [Abstract] [Full Text] [Related]

  • 16. Long-term neuropsychiatric consequences of "ecstasy" (MDMA): a review.
    Montoya AG, Sorrentino R, Lukas SE, Price BH.
    Harv Rev Psychiatry; 2002 Nov 01; 10(4):212-20. PubMed ID: 12119307
    [Abstract] [Full Text] [Related]

  • 17. [3,4-methylenedioxymethamphetamine ('ecstasy'): its long-term emotional and cognitive effects, and serotonin depletion].
    Molero-Chamizo A.
    Rev Neurol; 2002 Nov 01; 41(2):108-14. PubMed ID: 16028190
    [Abstract] [Full Text] [Related]

  • 18. Neurological and psychopathological sequelae associated with a lifetime intake of 40,000 ecstasy tablets.
    Kouimtsidis C, Schifano F, Sharp T, Ford L, Robinson J, Magee C.
    Psychosomatics; 2006 Nov 01; 47(1):86-7. PubMed ID: 16384814
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Long-term effects of 'ecstasy' abuse on the human brain studied by FDG PET.
    Buchert R, Obrocki J, Thomasius R, Väterlein O, Petersen K, Jenicke L, Bohuslavizki KH, Clausen M.
    Nucl Med Commun; 2001 Aug 01; 22(8):889-97. PubMed ID: 11473208
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.